Author of the publication

Temporal Trends in Use of Composite End Points in Major Cardiovascular Randomized Clinical Trials in Prominent Medical Journals.

, , , , , and . Circulation. Cardiovascular quality and outcomes, 10 (10): e003753 (October 2017)Comparacions múltiples; Composite endpoints; CV.
DOI: 10.1161/CIRCOUTCOMES.117.003753

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials., , , , , , , , , and 3 other author(s). BMJ (Clinical research ed.), (January 2013)7139<m:linebreak></m:linebreak>JID: 8900488; OID: NLM: PMC3541470; epublish;<m:linebreak></m:linebreak>Protocol; RCT.Declaración SPIRIT 2013 : definición de los elementos estándares del protocolo de un ensayo clínico *, , , , , , , , , and 9 other author(s). Revista panamericana de salud pública = Pan American journal of public health, 38 (6): 506-514 (2015)Protocol; RCT.Systematic review and evaluation of web-accessible tools for management of diabetes and related cardiovascular risk factors by patients and healthcare providers., , , , , and . JAMIA, 19 (4): 514-522 (2012)A tutorial on methods to estimating clinically and policy-meaningful measures of treatment effects in prospective observational studies: a review., and . The international journal of biostatistics, 7 (1): 6 (January 2011)6729<m:linebreak></m:linebreak>TY: GENERIC; J2: ijb; M1: 1;<m:linebreak></m:linebreak>Mesures de resultats; Observacionals; Propensity score.Temporal Trends in Use of Composite End Points in Major Cardiovascular Randomized Clinical Trials in Prominent Medical Journals., , , , , and . Circulation. Cardiovascular quality and outcomes, 10 (10): e003753 (October 2017)Comparacions múltiples; Composite endpoints; CV.How to ascertain drug safety in the context of benefit. Controversies and concerns., , , , , , , , , and 10 other author(s). The Journal of rheumatology, 36 (9): 2114-21 (September 2009)5429<m:linebreak></m:linebreak>JID: 7501984; 0 (Antirheumatic Agents); ppublish;.